Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 18/20 | 0.49 |
| ▸ | PTGDR | Q13258 | 3/20 | 0.46 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.45 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL833465 | 1.00 | PTGDR2 (0.49) | PTGDR2PTGDRPTGER2TBXA2RNPC1 | |
| SCHEMBL833691 | 1.00 | PTGDR2 (0.49) | PTGDR2PTGDRPTGER2TBXA2RNPC1 | |
| SCHEMBL832342 | 0.92 | PTGDR2 (0.53) | PTGDR2PTGDRPTGER2TBXA2RNPC1 | |
| SCHEMBL832341 | 0.92 | PTGDR2 (0.53) | PTGDR2PTGDRPTGER2TBXA2RNPC1 | |
| SCHEMBL834210 | 0.92 | PTGDR2 (0.53) | PTGDR2PTGDRPTGER2TBXA2RNPC1 | |
| SCHEMBL833578 | 0.92 | PTGDR2 (0.55) | PTGDR2PTGDRPTGER2TBXA2R | |
| SCHEMBL833054 | 0.92 | PTGDR2 (0.55) | PTGDR2PTGDRPTGER2TBXA2R | |
| SCHEMBL833055 | 0.92 | PTGDR2 (0.55) | PTGDR2PTGDRPTGER2TBXA2R | |
| SCHEMBL833598 | 0.91 | PTGDR2 (0.49) | PTGDR2PTGDRPTGER2TBXA2RNPC1 | |
| SCHEMBL832255 | 0.91 | PTGDR2 (0.49) | PTGDR2PTGDRPTGER2TBXA2RNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143304-B2 | (3-amino-1,2,3,4-tetrahydro-9 H-carbazol-9-yl)-acetic acid derivatives | ACTELION PHARMACEUTICAL LTD. (CH) | 2012-03-27 | — | — | US | claimed |
| EP-2051962-B1 | (3-AMINO-1,2,3,4-TETRAHYDRO-9H-CARBAZOL-9-YL)-ACETIC ACID DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2011-10-26 | — | — | EP | claimed |
| US-20100190830-A1 | (3-Amino-1,2,3,4-Tetrahydro-9H-Carbazol-9-yl)-Acetic Acid Derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-07-29 | — | — | US | claimed |
| US-8143304-B2 | (3-amino-1,2,3,4-tetrahydro-9 H-carbazol-9-yl)-acetic acid derivatives | ACTELION PHARMACEUTICAL LTD. (CH) | 2012-03-27 | — | — | US | disclosed |
| EP-2051962-B1 | (3-AMINO-1,2,3,4-TETRAHYDRO-9H-CARBAZOL-9-YL)-ACETIC ACID DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2011-10-26 | — | — | EP | disclosed |
| EP-2316824-A1 | (3-Amino-1,2,3,4-tetrahydro-9H-carbazoI-9-yl)-acetic acid derivates | Actelion Pharmaceuticals Ltd. (CH) | 2011-05-04 | — | — | EP | disclosed |
| US-20100190830-A1 | (3-Amino-1,2,3,4-Tetrahydro-9H-Carbazol-9-yl)-Acetic Acid Derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190830-A1 | (3-Amino-1,2,3,4-Tetrahydro-9H-Carbazol-9-yl)-Acetic Acid Derivatives | PTGDR, PTGER1, PTGIR | PTGDR2 4/4885PTGDR 1/4885PTGER2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.